MedTrace Logo

Assessment of Serum Catestatin Level in Acne Vulgaris Patients

NCT07054398 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-07-08

No results posted yet for this study

Summary

Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults.

Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Isotretinoin

* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons. * Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris.

Sponsors & Collaborators

  • Aswan University

    lead OTHER

Principal Investigators

  • Moustafa Adam Ali El Taieb, Professor · Dermatology, Venereology and Andrology. Faculty of Medicine,Aswan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2026-01-01
Completion
2026-01-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07054398 on ClinicalTrials.gov